CLINICAL_TRIALS
trial_result
· 2026-06-09
Clinical Trial Update: Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere [Phase 3]
Summary
Phase 3 clinical trial evaluating TareSphere for unresectable hepatocellular carcinoma; currently active not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Conditions: Unresectable Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING